Inclusion Criteria:  Patients received a questionnaire, if all of the following applied:  Patients intent to use Iberogast® for the treatment of functional gastrointestinal symptoms (e.g. stomach pain, abdominal cramps, nausea, bloating, flatulence and heartburn) as well as defined functional dyspepsia (FD) and irritable bowel syndrome (IBS). Patients suffered more from intestine-related complaints Patients expressed their interest in participating in the study Patients were willing and able to answer the questionnaire completely and plausibly  Exclusion Criteria:  Patients did not receive a questionnaire, if  Patients did not currently use Iberogast® to treat gastrointestinal diseases such as irritable stomach and irritable bowel syndrome (medicine cabinet & travel medicine cabinet) or bought the product for someone else Patients did not give a specific reason for treatment Patients did not show interest in participating Patients suffered exclusively from diarrhea and constipation Patients suffered exclusively from heartburn.